Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes: [[:Category:Antidepressants|Antidepressant]]

& mechanism

: 5-HT1B/1D agonist

or None

Use the filters below to narrow your results.

Amitriptyline (hydrochloride) (1) · Bupropion (1) · Desvenlafaxine (succinate) (1) · Doxepin (hydrochloride) (1) · Fluvoxamine (maleate) (1) · Mirtazapine (1) · Paroxetine (HCl; mesylate as Pexeva) (1) · Venlafaxine (1)

Effexor XR, Effexor IR (discontinued in US, generic widely available) (1) · Elavil (US brand discontinued; generic widely available), Endep, Tryptizol (1) · Luvox (US brand discontinued; generic widely available), Luvox CR, Faverin (other markets) (1) · Paxil (IR), Paxil CR (controlled-release), Brisdelle (low-dose for menopausal vasomotor symptoms), Pexeva (paroxetine mesylate) (1) · Pristiq (1) · Remeron (US brand discontinued; generic widely available), Remeron SolTab (ODT) (1) · Sinequan (oral antidepressant, US brand discontinued), Silenor (low-dose for insomnia), Prudoxin / Zonalon (topical cream) (1) · Wellbutrin (IR, SR, XL), Zyban (smoking cessation), Aplenzin (hydrobromide salt), Forfivo XL (1)

15 mg PO at bedtime, titrate to 30-45 mg/day after 1-2 weeks. '''Counterintuitive dose paradox''': lower doses (7.5-15 mg) are more sedating than higher doses because H1 antihistamine effect dominates at low dose (1) · 50 mg PO at bedtime; titrate by 50 mg every 4-7 days to clinical effect. Total daily doses >100 mg divided BID. Luvox CR: 100 mg PO once daily, may titrate to 300 mg/day (1) · 50 mg PO once daily ('''no titration required''', distinguishing it favorably from venlafaxine) (1) · Depression (rarely used now): 25-75 mg PO at bedtime, titrate to 150 mg/day. Neuropathic pain / migraine prophylaxis: 10-25 mg at bedtime, titrate by 10-25 mg weekly to 50-100 mg/day. Elderly: 10 mg at bedtime (Beers-list cautions apply) (1) · Depression: 25-75 mg/day to start, titrate to 75-150 mg/day at bedtime. Insomnia (Silenor): 3 mg PO 30 minutes before bedtime, max 6 mg. Topical (Prudoxin): apply to affected area every 3-4 hours (1) · MDD/GAD: 20 mg PO once daily. Panic disorder: 10 mg titrating to 40 mg. OCD: 20 mg titrating to 40-60 mg. CR: 25 mg/day. Brisdelle: 7.5 mg at bedtime for hot flashes (1) · SR 150 mg PO once daily for 3 days, then 150 mg BID. XL 150 mg PO once daily for 4 days, then 300 mg once daily. Zyban (smoking cessation) 150 mg daily for 3 days, then 150 mg BID (1) · XR 37.5 mg PO once daily for 4-7 days, then 75 mg/day; titrate by 75 mg every ≥4 days to clinical effect. IR 25-37.5 mg BID-TID (1)

Capsules 10, 25, 50, 75, 100, 150 mg; oral concentrate 10 mg/mL; Silenor tablets 3, 6 mg; topical cream 5% (Prudoxin, Zonalon) (1) · ER tablets 25, 50, 100 mg (1) · IR tablets 10, 20, 30, 40 mg; CR tablets 12.5, 25, 37.5 mg; oral suspension 10 mg/5 mL; Brisdelle capsules 7.5 mg (1) · IR tablets 25, 37.5, 50, 75, 100 mg; XR capsules 37.5, 75, 150, 225 mg (1) · IR tablets 25, 50, 100 mg; Luvox CR capsules 100, 150 mg (1) · SR tablets 100, 150, 200 mg; XL tablets 150, 300 mg; IR tablets 75, 100 mg (less common); Aplenzin (bupropion hydrobromide) 174, 348, 522 mg (1) · Tablets 10, 25, 50, 75, 100, 150 mg (1) · Tablets 7.5, 15, 30, 45 mg; orally disintegrating tablets (SolTab) 15, 30, 45 mg (1)

225 mg/day outpatient (XR); 375 mg/day inpatient (IR divided TID); 75 mg/day in moderate hepatic impairment (1) · 300 mg/day (depression, hospitalized); 150 mg/day outpatient; 6 mg/day for insomnia (1) · 300 mg/day (historical hospitalized inpatient depression); 150 mg/day outpatient typical ceiling (1) · 300 mg/day (IR or CR) (1) · 45 mg/day (1) · 450 mg/day; doses above this raise seizure risk steeply (1) · 50 mg/day (IR); 62.5 mg/day (CR); 60 mg/day (OCD) (1) · 50 mg/day (no efficacy benefit shown for higher doses despite the 100 mg strength being available) (1)

Oral (8) · topical (1)

1-2 weeks for antidepressant effect; smoking-cessation effect builds over the first 1-2 weeks (1) · Antidepressant effect emerges over 1-2 weeks (2) · Antidepressant effect over 1-2 weeks; anxiolytic effect over 4-6 weeks (1) · OCD effect over 1-2 weeks initial, with full effect typically 6-12 weeks; among the slowest SSRIs for OCD response (1) · Sleep effect from first dose; analgesic and migraine-prophylaxis effect 1-4 weeks; antidepressant effect 4-6 weeks (1) · Sleep effect from first dose; antidepressant effect over 1-4 weeks (2)

24 hours (1) · 24 hours (HS dosing) (3) · 24 hours (once-daily dosing) (1) · 24 hours (XR); 12 hours (IR) (1) · BID at higher doses (IR); once-daily (CR) (1) · SR ~12 hours; XL 24 hours (1)

20-40 hours'"`UNIQ--ref-00000023-QINU`"' (1) · Amitriptyline 10-50 hours (highly variable); nortriptyline active metabolite 18-44 hours'"`UNIQ--ref-00000026-QINU`"' (1) · Bupropion ~21 hours; hydroxybupropion (active metabolite) ~20-37 hours'"`UNIQ--ref-00000023-QINU`"' (1) · Venlafaxine 5 hours; desvenlafaxine active metabolite 11 hours'"`UNIQ--ref-00000026-QINU`"' (1) · ~11 hours'"`UNIQ--ref-0000001A-QINU`"' (1) · ~15 hours (IR)'"`UNIQ--ref-00000023-QINU`"' (1) · ~15 hours (parent); nordoxepin active metabolite ~30 hours'"`UNIQ--ref-00000020-QINU`"' (1) · ~21 hours (with nonlinear pharmacokinetics from CYP2D6 autoinhibition)'"`UNIQ--ref-0000002B-QINU`"' (1)

Highly variable due to saturable first-pass metabolism'"`UNIQ--ref-0000002C-QINU`"' (1) · ~30% (oral)'"`UNIQ--ref-00000021-QINU`"' (1) · ~45%'"`UNIQ--ref-00000027-QINU`"' (1) · ~5-20% (extensive first-pass), highly variable between individuals'"`UNIQ--ref-00000024-QINU`"' (1) · ~50% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) · ~50% (oral; substantial first-pass)'"`UNIQ--ref-00000024-QINU`"' (1) · ~53% (oral)'"`UNIQ--ref-00000024-QINU`"' (1) · ~80% (oral)'"`UNIQ--ref-0000001B-QINU`"' (1)

'''Among the least preferred SSRIs in pregnancy.''' Observational signal for cardiac malformations (atrial and ventricular septal defects) with first-trimester exposure, and the most severe neonatal adaptation syndrome of any SSRI with third-trimester exposure'"`UNIQ--ref-0000002D-QINU`"' (1) · Limited human data; some animal cardiac signal not clearly replicated in human cohort studies; observational signals inconclusive.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited human data; some observational signals reassuring relative to other antidepressants.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Observational signal for neonatal adaptation syndrome with late-pregnancy exposure (SNRI class effect).[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Observational signal for neonatal adaptation syndrome with late-pregnancy exposure; weigh against the risks of untreated maternal depression.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Observational signal for neonatal adaptation syndrome with third-trimester exposure (SSRI class effect).[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Older agent with substantial use experience; observational signals not clearly causal.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · TCA class signal; limited human data specific to doxepin.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

[[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults. Not controlled'"`UNIQ--ref-00000025-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-0000001C-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000022-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000025-QINU`"' (2) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000028-QINU`"' (2) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-0000002E-QINU`"' (1)

Showing below up to 8 results in range #1 to #8.